NEW YORK (GenomeWeb News) – StemCells today announced that it has completed its acquisition of UK-based Stem Cell Sciences for 2.65 million shares of its common stock and $700,000 in cash.

Based on the Tuesday closing price of StemCells' stock ($1.67), the deal is valued at around $4.4 million, lower than the $4.8 million estimated when the deal was signed in early March. SCS' shareholders overwhelmingly approved the deal last week at an extraordinary general meeting.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.